Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Urinbiomarker-basiertes Diagnose- und Überwachungssystem für chronische Nierenerkrankungen und reale Wirksamkeit von SGLT2-Hemmern

4. November 2026 aktualisiert von: Instituto de Investigación Biomédica de Salamanca

Diagnose- und Überwachungssystem für chronische Nierenerkrankungen basierend auf Urinbiomarkern und präventiver Behandlung mit dem SGLT2-Inhibitor Empagliflozin

This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.

No investigational product is assigned, and medical practice or prescription patterns are not altered.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a real-world, observational study with prospective follow-up and retrospective baseline data when available, conducted at the Nephrology Department of the University Hospital of Salamanca, Spain.

The project integrates translational and clinical components:

  1. validation of a urinary biomarker panel obtained through differential proteomics for early detection and monitoring of CKD progression, and
  2. evaluation of the effectiveness and safety of SGLT2i in routine clinical practice.

A total of 300 adults with CKD stages 2-4 will be included (150 initiating SGLT2i and 150 matched controls). Participants will be followed for 12 months (baseline, 6, and 12 months). Data will be extracted exclusively from electronic health records and laboratory systems.

The primary outcome is the annual decline rate of estimated glomerular filtration rate (eGFR, CKD-EPI 2021). Secondary outcomes include a composite renal endpoint (≥40% sustained eGFR decline, renal replacement therapy, transplantation, or renal death), cardiovascular hospitalization, all-cause mortality, adverse drug reactions (ADRs), and real-world patterns of SGLT2i use.

Exploratory analyses will assess associations between urinary biomarkers and clinical outcomes.

The study follows Spanish regulations for observational studies with medicinal products (Real Decreto 957/2020), with ethics approval and informed consent for biological samples.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

300

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Carlos Martínez Salgado, PhD
  • Telefonnummer: +34616129633
  • E-Mail: carlosms@usal.es

Studienorte

      • Salamanca, Spanien
        • Rekrutierung
        • Hospital Universitario de Salamanca
        • Kontakt:
          • Carlos Martínez Salgado, PhD
          • Telefonnummer: +34616129633
          • E-Mail: carlosms@usal.es
        • Kontakt:
          • Pilar Fraile Gómez, MD, PhD
          • Telefonnummer: +34923291100
          • E-Mail: pilarfg@usal.es

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

16 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Participants with chronic kidney disease (CKD) stages 2-4.

Beschreibung

Inclusion Criteria:

  • ≥18 years old
  • Diagnosed with chronic kidney disease (KDIGO stages 2-4)
  • Life expectancy ≥12 months
  • Available clinical and laboratory data in the electronic medical record

Exclusion Criteria:

  • Current or recent renal replacement therapy or kidney transplantation
  • End-stage renal disease
  • Participation in interventional trials that may affect outcomes
  • Allergy or intolerance to SGLT2i (for exposed cohort)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Empagliflozin Treatment Group

Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety.

Oral empagliflozin (10-25 mg daily) for 12 months

Control group

Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up.

These patients receive standard clinical care according to local and national guidelines.

They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems.

Reasons for non-initiation of SGLT2i are documented systematically and may include:

Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio <200 mg/g, eGFR <20 mL/min/1.73 m² for empagliflozin or <25 for dapagliflozin), or

Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity.

Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over).

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in urinary biomarker panel expression (proteomic fingerprint)
Zeitfenster: Baseline, 6 months, 12 months

Quantitative assessment of urinary biomarkers (including KIM-1, transferrin, IGFBP7, TIMP-2, among others) to evaluate disease progression and treatment response. Urinary biomarkers will be assessed using liquid chromatography-mass spectrometry (LC-MS/MS)-based differential proteomic analysis. Biomarker expression will be quantified as log2 fold change with false discovery rate (FDR) correction. Selected biomarkers will be validated using enzyme-linked immunosorbent assay (ELISA) or equivalent immunoassays. Biomarker concentrations will be normalized to urinary creatinine levels.

Baseline, 6 months, 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in estimated glomerular filtration rate (eGFR)
Zeitfenster: Baseline, 6 months, 12 months

Evaluation of renal function improvement or stabilization during SGLT2 inhibitor treatment.

Baseline, 6 months, 12 months
Histopathological improvement of renal tissue (animal study)
Zeitfenster: Monthly up to 9 months

Monthly analysis of renal fibrosis, inflammation, and extracellular matrix accumulation in preclinical models treated with empagliflozin.

Monthly up to 9 months
Monitoring of adverse events of empagliflozin in CKD patients without diabetes
Zeitfenster: From baseline to 12 months

Adverse events (AEs) will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE, latest version), including severity grading and assessment of causality related to treatment.

Serious adverse events (SAEs) and discontinuations due to AEs will be specifically tracked by the investigator.

From baseline to 12 months
Change in estimated glomerular filtration rate (eGFR)
Zeitfenster: From baseline to 12 months

Change in renal function assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation during empagliflozin treatment using the Serum creatinine-based CKD-EPI equation.

From baseline to 12 months
Change in serum creatinine
Zeitfenster: From baselinte to 12 months

hange in serum creatinine levels to assess renal safety during treatment with empagliflozin by standard clinical laboratory assay (mg/dL).

From baselinte to 12 months
Change in urinary albumin-to-creatinine ratio
Zeitfenster: From baseline to 12 months

Change in urinary albumin-to-creatinine ratio as a marker of renal damage and safety during empagliflozin treatment by standard urine laboratory testing (mg/g creatinine).

From baseline to 12 months
Change in serum electrolyte levels
Zeitfenster: From baseline to 12 months

Change in serum sodium and potassium levels to evaluate electrolyte safety during empagliflozin treatment by standard clinical laboratory testing (mmol/L).

From baseline to 12 months
Change in liver function tests
Zeitfenster: From baseline to 12 months

Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to assess hepatic safety by standard clinical laboratory assays (U/L).

From baseline to 12 months
Change in glycated hemoglobin (HbA1c)
Zeitfenster: From baseline to 12 months.

Change in HbA1c levels to monitor metabolic safety in non-diabetic CKD patients treated with empagliflozin by standard laboratory assay (%).

From baseline to 12 months.
Change in hematological parameters
Zeitfenster: From baseline to 12 months

Change in complete blood count parameters to evaluate hematological safety during treatment by standard clinical laboratory testing.

From baseline to 12 months
Change in blood pressure
Zeitfenster: From baseline to 12 months

Assessment of changes in both blood pressures (systolic and diastolic), by Standard sphygmomanometer measurement (mmHg).

From baseline to 12 months
Change in body weight
Zeitfenster: From baseline to 12 months

Change in body weight to assess tolerability and volume status during empagliflozin treatment by calibrated clinical scale (kg).

From baseline to 12 months
Discontinuation due to treatment intolerance
Zeitfenster: From baseline to 12 months

Number and proportion of participants who permanently discontinue empagliflozin due to treatment-related intolerance or adverse events. It will be achieved trough clinical visit records and adverse event reporting.

From baseline to 12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Carlos Martínez Salgado, PhD, University of Salamanca
  • Hauptermittler: Pilar Fraile Gómez, MD, PhD, University of Salamanca

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. April 2026

Primärer Abschluss (Geschätzt)

1. April 2028

Studienabschluss (Geschätzt)

1. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

18. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. Januar 2026

Zuerst gepostet (Tatsächlich)

16. Januar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • PI25/00053

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.

IPD-Sharing-Zeitrahmen

Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.

IPD-Sharing-Zugriffskriterien

Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ANALYTIC_CODE

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .